Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158369 | 0.61 | CYP2A6 (0.47) | AHRPIM1JAK2CHEK1AURKA | |
| SCHEMBL1204761 | 0.61 | CYP2A6 (0.43) | AHRPIM1HTTMAPT | |
| SCHEMBL7794514 | 0.61 | ALOX15 (0.33) | AHRPIM1HTTJAK2CHEK1 | |
| SCHEMBL29595200 | 0.59 | CYP2A6 (0.52) | AHRPIM1HTTJAK2CHEK1 | |
| SCHEMBL1569370 | 0.59 | CYP2A6 (0.52) | AHRPIM1HTTJAK2CHEK1 | |
| SCHEMBL258689 | 0.59 | PIM1 (0.55) | AHRPIM1MAPT | |
| SCHEMBL20162082 | 0.59 | CYP2A6 (0.37) | AHRPIM1HTTJAK2CHEK1 | |
| SCHEMBL3100971 | 0.58 | MAPT (0.35) | AHRPIM1MAPT | |
| SCHEMBL5537475 | 0.58 | LMNA (0.33) | HTT | |
| SCHEMBL31267442 | 0.58 | CYP2A6 (0.39) | AHRPIM1HTTJAK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103111-A1 | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-01 | — | — | US | disclosed |
| US-6274556-B1 | ADMINISTERING POLYPEPTIDE DERIVATIVE TO TREAT INFLAMMATORY BOWEL DISEASE AND TO PREVENT LEUKOCYTE INFILTRATION INTO TISSUES | MILLENNIUM PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6037324-A | MADCAM-1 (MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1); USEFUL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND OTHER DISEASES INVOLVING LEUKOCYTE INFILTRATION OF THE GASTROINTESTINAL TRACT OR OTHER MUCOSAL TISSUES | LEUKOSITE, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0871670-A2 | INHIBITORS OF MAdCAM-1-MEDIATED INTERACTIONS AND METHODS OF USE THEREFOR | Leukosite, Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997025351-A2 | INHIBITORS OF MAdCAM-1-MEDIATED INTERACTIONS AND METHODS OF USE THEREFOR | LEUKOSITE, INC. (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103111-A1 | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor | VCAM1, ICAM1, SELPLG | AHR 4662/4885PIM1 2042/4885HTT 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.